Endocrine Society GUIDELINES Bundle (free trial)

Pediatric Obesity

Endocrine Society GUIDELINES Apps brought to you free of charge courtesy of Guideline Central. All of these titles are available for purchase on our website, GuidelineCentral.com. Enjoy!

Issue link: https://eguideline.guidelinecentral.com/i/1140160

Contents of this Issue

Navigation

Page 23 of 27

Treatment 24 Table 5. Medications Studied for the Long-Term Treatment of Obesity (cont'd) Drug Status Common Side Effects Monitoring and Contraindications Bupropion plus naltrexone a Approved for long-term use in adults Nausea, constipation, headache, vomiting, dizziness, insomnia, dry mouth, diarrhea Monitor HR, BP. Do not administer to patients with a history of seizure disorders or with anorexia or bulimia nervosa or to patients who are using opioids or abruptly discontinuing use of alcohol, benzodiazepines, barbiturates, or antiseizure medications. ere is potential increased risk of suicidality. Drugs in development or used off-label that may act centrally as anorexigenic medications. Recombinant human leptin, metreleptin a is drug is under investigation. In monotherapy it was successful for treating leptin deficiency. Headache, abdominal pain is drug is useful only in leptin deficiency. Antibodies with neutralizing activity have been identified in patients treated with metreleptin. T cell lymphoma has been reported in patients with acquired generalized lipodystrophy. A risk evaluation and mitigation strateg y should be in place to prevent inappropriate prescription.

Articles in this issue

Archives of this issue

view archives of Endocrine Society GUIDELINES Bundle (free trial) - Pediatric Obesity